Lexeo Therapeutics (LXEO) Other Operating Expenses (2023 - 2026)

Lexeo Therapeutics has disclosed Other Operating Expenses across 4 years of filings, most recently posting -$4.7 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at -$4.7 million, up 62.52% year-over-year; the trailing twelve-month figure through Mar 2026 was -$12.9 million (up 60.41% YoY), and the FY2025 annual result was -$37.0 million, down 48.06% from the prior year.
• Other Operating Expenses came in at -$4.7 million for Q1 2026 at Lexeo Therapeutics, down from $6.9 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $53.1 million in Q4 2023 to a low of -$12.6 million in Q1 2025.
• The 4-year median for Other Operating Expenses is -$4.5 million (2024), against an average of $264300.0.
• Peak annual rise in Other Operating Expenses reached 158.39% in 2025, while the deepest fall reached 209.04% in 2025.
• Lexeo Therapeutics' Other Operating Expenses stood at $53.1 million in 2023, then sank by 122.21% to -$11.8 million in 2024, then jumped by 158.39% to $6.9 million in 2025, then tumbled by 168.35% to -$4.7 million in 2026.
• The last three Other Operating Expenses figures came in at -$4.7 million (Q1 2026), $6.9 million (Q4 2025), and -$2.9 million (Q3 2025), per Business Quant data.